Abstract

Introduction. Osteoarthritis is considered to be the most common form of arthritis and a leading disability cause worldwide, especially due to the painful symptom. The latter is a clinical marker in evaluating the limits of joint mobility and therefore, the pain reduction is a goal of the recovery treatment for patients with knee osteoarthritis. The purpose of this study was to show whether the pain phenomenon characteristic of knee osteoarthritis can be reduced by electrotherapy, even in the context of the COVID-19 pandemic. Material and method. The study lasted 5 months and included 171 patients diagnosed clinically and radiologically with knee osteoarthritis. The followed parameters were pain, physical dysfunction in daily activities, anxiety and quality of life. Results and discussions. The two groups of studied patients were homogeneous in terms of weight by gender and age groups. The evaluation of patients according to scales enabled the registration of statistically significant values, the value of p <0.05, which explains the validation of the working hypothesis. The feeling of pain is closely related to the level of anxiety. Conclusions. Analgesic electrotherapy significantly reduced the pain syndrome of the patients for whom it was used. It has been shown that the patients' anxiety can influence the pain phenomenon. Given the conditions caused by the Covid-19 pandemic, the anxiety of the patients who were in the outpatient department to receive recovery treatment was increased, but after the recovery treatment there was a decrease, so these patients' quality of life increased.

Keywords: pain, analgesic electrotherapy, knee osteoarthritis, recovery treatment.
one of the goals of recovery treatment for patients with knee osteoarthritis (13).

The study of Abdel-Aziem in 2018 (14) showed the effect of the physiotherapeutic program on knee osteoarthritis according to the intensity of the pain. This parameter, pain, is considered one of the factors responsible for the evolution of knee osteoarthritis. Dworkin et al. in 2011 concluded that the pain and severity degree are correctly assessed by using the VAS scale and the WOMAC pain subscale (15).

It was found that people diagnosed with knee osteoarthritis had higher pain intensities in comparison to witnessed for the same level of pressure stimuli, but also for lower pain or pressure level (16).

Some research has shown the role and importance of spinal relief in the perception of pain, because at this level there are mechanisms that can modulate the nociceptive transmission.

The pain transmission can be influenced at this level by inflows coming from the periphery as well as from the superior nerve structures (17). In this context, electrotherapy in knee osteoarthritis is also used for algies purposes by blocking the conduction of the impulse through the sensitive nerve fibers.

The purpose of this study was to show whether the pain phenomenon characteristic of knee osteoarthritis can be diminished by electrotherapy, even in the context of the COVID-19 pandemic.

Material and method

The study was conducted over a period of 5 months, from April to August 2020, on outpatients and included a number of 171 patients diagnosed clinically and radiologically with knee osteoarthritis. They followed, in series, a number of 15 days of treatment, in a rhythm of 1 session per day. The used treatment was pharmacological, according to the guidelines (NSAIDs in general administration and in topical one, analgesics) (18) and non-pharmacological (weight loss, avoidance of rough terrain, prolonged orthostatism, electrotherapy and physiotherapy). The patients were evaluated in the beginning of the treatment and at its end, and also 6 weeks later, when they returned to control.

The criteria for the inclusion in the group were: patients with a clinical and radiological diagnosis of knee osteoarthritis over 3 months, over 40 years old, without comorbidities in decompensated stages, without neuromental disorders, patients who agreed to participate in the study.

The criteria for the exclusion from the group were: patients under the age of 40, who also had cardiac, respiratory, renal, digestive disorders in a decompensated stage, non-compliant, who did not agree to participate in the study.

The patients signed the consent for the applied recovery treatment, then the study was carried out by respecting the norms of ethics and deontology according to the legislation in force.

The followed parameters were pain, physical dysfunction in daily activities, anxiety and quality of life. For pain we applied the VAS scale (0- no pain, 10 – maximum pain) and also the WOMAC pain subscale. The static pain was assessed (while sitting, sleeping, orthostatism) and the dynamic pain (while walking, climbing / descending stairs) in which 0 = no pain and 20 = maximum pain.

For the physical dysfunction, the WOMAC subscale was considered (activities at home and outside), the value 0 = optimal development of activities and 68 = limitation of daily activities.

In assessing the patients’ quality of life we used the QOL scale (16 means a quality of life influenced by nociceptive factors, the value 112 = well-being, without pain or other symptoms). We considered it useful, in the situation created by the COVID-19 pandemic, to apply the anxiety assessment scale strictly related to the disease, not the one determined by previous anxiety states. In this sense we used the State Trait Anxiety Inventory (S.T.A.I.) scale and namely the subscale STAI – X1 where the values vary from 20 (reduced anxiety) to 80 (increased anxiety).

For this purpose, for the recovery treatment the patients of the group were divided into 2 study groups, namely: the L1 group (83 patients) who received, in addition to the pharmacological treatment, low frequency currents (Transcutaneous electrical nerve stimulation -frequency of 15-100 Hz, duration of 30-200 ms, Intensity 10-40 mA, with the rapid installation of the analgesic effect), medium frequency (interferential -with analgesic effect by increasing the pain level and changing the pain perception, vasomotor, hyperemic and resorptive) and ultrasound (analgesic effect by inhibiting the transmission of nociceptive information, anti-inflammatory due to vasomotor and metabolic action, but also muscle relaxant - frequency 1 MHz, intensity of 0.5 - 0.7W/cm², duration of 5 minutes, pulse application regime to eliminate the thermal effect (19).

The L2 group (88 patients) who received only pharmacological treatment (they showed increased anxiety in the context of the pandemic and did not want to participate in electrotherapy sessions).

However, the patients of the L2 group accepted to participate in individual physiotherapy sessions, as well as the patients in the L1 group.

The kinetotherapy program lasted for 30 minutes a session, it took place daily and included passive mobilizations, active mobilizations and active mobilizations with resistance, but also coordination and balance exercises, useful in recovering posture and gait.

The L1 group included 83 patients, of which 41 (49.39%) were female and 42 (50.61%) were male, whereas the L2
study group included 88 patients, of which 7 (53.41%) were female and 41 (46.59%) male.  

Table no. 1. Distribution of patients according to the study groups and age groups

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>LOT L1</th>
<th>LOT L2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female/Male gender</td>
<td>n</td>
<td>%</td>
</tr>
<tr>
<td>40-49 years</td>
<td>19</td>
<td>23.89</td>
</tr>
<tr>
<td>50-69 years</td>
<td>18</td>
<td>21.69</td>
</tr>
<tr>
<td>70-79 years</td>
<td>17</td>
<td>20.47</td>
</tr>
<tr>
<td>&gt; 80 years</td>
<td>8</td>
<td>9.64</td>
</tr>
</tbody>
</table>

The demographic data in the study were: patients' age, gender, living environment and body mass index. The patients' average age was 62±12.69 in the L1 group (min. 40, max. 82) and 60.5±12.91 in the L2 group (min. 40, max. 84).  

Table no. 2. Distribution of patients according to body mass index

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>LOT L1</th>
<th>LOT L2</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI (Kg/m²)</td>
<td>n</td>
<td>%</td>
</tr>
<tr>
<td>29.39±4.29</td>
<td>29</td>
<td>41.57</td>
</tr>
<tr>
<td>Normal weight (19-24.99)</td>
<td>13</td>
<td>15.66</td>
</tr>
<tr>
<td>Overweight (25-29.99)</td>
<td>38</td>
<td>45.78</td>
</tr>
<tr>
<td>Obesity (&gt;30)</td>
<td>33</td>
<td>38.55</td>
</tr>
</tbody>
</table>

Statistical analysis

The data obtained from the initial, final and control evaluations were statistically processed by using Microsoft Excel 10. The median, the standard deviation, and the t-student test were calculated to test the working hypothesis. The chosen level of statistical significance was 5%, ie. its value should be p<0.05.  

Results

The pain evaluated by the VAS scale showed statistically significant results in both groups, registering in L1 group a decrease by 42.86% at the end of the treatment and 50% during the control, in comparison to L2 group in which the pain decreased by 28.57% at the end of the treatment and by 40% during the control. The pain phenomenon assessed with the WOMAC subscale registered a decrease by 28.57% in the L1 group at the end of the treatment and of 50% during the control, whereas in the L2 group the reduction of pain was by 21.43% at the end of the treatment and by 45.46% during the control.

The body mass index decreased in the L1 group by 2.44% at the end of the treatment and by 2.55 during the control, whereas in the L2 group it decreased by 1.59% at the end of the treatment and by 2.69% during the control. Also, the daily activities improved in the L1 group by 36.17% at the end of the treatment and by 50% during the control, whereas in the L2 group the improvement was by 29.41% at the end of the treatment and by 50% during the control. Anxiety decreased in the L1 group by 36.84% at the end of the treatment and by 29.63% during the control.  

Table no. 3. Evolution of the parameters in the two groups

<table>
<thead>
<tr>
<th>SCALe</th>
<th>L1 GROUP</th>
<th>L2 GROUP</th>
</tr>
</thead>
<tbody>
<tr>
<td>VAS</td>
<td>0.0247</td>
<td>0.0258</td>
</tr>
<tr>
<td>WOMAC pain</td>
<td>0.0156</td>
<td>0.0086</td>
</tr>
<tr>
<td>WOMAC physical function</td>
<td>0.0435</td>
<td>0.0326</td>
</tr>
<tr>
<td>QOL</td>
<td>0.0055</td>
<td>0.0038</td>
</tr>
<tr>
<td>STAI X-1</td>
<td>0.0377</td>
<td>0.0311</td>
</tr>
</tbody>
</table>

Discussion

The objectives of the treatment for the patients diagnosed with knee osteoarthritis were mainly: the reduction of pain, anxiety caused by the COVID-19 pandemic, increased muscle strength, muscle toning, coordination to achieve static and dynamic balance, increased mobility of the joints, quality of life and rapid reintegration into the socio-familial environment.

The applied electrotherapy had an analgesic, anti-inflammatory, resorbive purpose. Kinetotherapy was applied in order to improve physical and mental function, whereas the inhibiting role of nociception is known at the local and central level. The two studied groups of patients were homogeneous in terms of weight, gender and age. The evaluation of patients based on scales enabled the registration of statistically significant values, the value of p <0.05, which explains the validation of the working hypothesis.  

Table 4. The values of the t-student test in the two groups of patients (T1-T2)

The L1 group that received analgesic electrotherapy recorded statistically significant values, as it is seen in the literature of specialty. The application of the kinetotherapy program also had a role in reducing the pain phenomenon. On the other hand, the results obtained by reducing the value of the body mass index by doing physical exercises correspond to the data in the literature that explain the role of physical activities in reducing pain and reducing body mass index (7).
The pain phenomenon in the context of knee osteoarthritis recorded a more significant decrease in the L1 group, which enabled the increase of patients' quality of life and the reduction of the anxious state caused by the disease and the pandemic context. The sensation of pain is closely related to the anxiety level, an observation that is also found in the study of Zubieta who showed that pain is a subjective experience having a genetic predisposition and being partially influenced by the administration of analgesics (20).

Conclusions
The individualized recovery treatment associated to the kinetotherapeutic program and an adequate diet enabled the attainment of statistically significant results. The analgesic electrotherapy significantly reduced the pain syndrome of the patients for whom it was used. It has been shown that patients' anxiety can influence the pain phenomenon. Given the conditions caused by the Covid-19 pandemic, the anxiety of the patients who were in the outpatient department to receive recovery treatment was increased. During the treatment, the anxiety condition decreased while the level of pain decreased.

Acknowledgements
All authors have read and approved this publication and had equal scientific contribution in publishing this material.

Abbreviations
NSAID -The non-steroidal anti-inflammatory drugs
VAS scale - Visual Analog Scale for Pain
WOMAC scale - Western Ontario and McMaster Universities Osteoarthritis Index
QOL scale –Quality of life
STAI -State Trait Anxiety Inventory
BMI-Body mass index

References: